.....T his is the first case of PRES during ipilimumab therapy. Increasing awareness of PRES is needed in patients who undergo anti–CTLA-4 therapies and develop irAEs such as hypophysitis in our patient. Autoimmune disorders are associated with an increased risk of PRES; autoimmune hypophysitis, however, does not seem to be implicated in the development of PRES. Further inves- tigations on the mechanisms of toxicity and risk factors for PRES are necessary
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma
FRASSOLDATI, Antonio;
2012
Abstract
.....T his is the first case of PRES during ipilimumab therapy. Increasing awareness of PRES is needed in patients who undergo anti–CTLA-4 therapies and develop irAEs such as hypophysitis in our patient. Autoimmune disorders are associated with an increased risk of PRES; autoimmune hypophysitis, however, does not seem to be implicated in the development of PRES. Further inves- tigations on the mechanisms of toxicity and risk factors for PRES are necessaryFile in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.